Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

233 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Potential therapeutic strategies to overcome acquired resistance to BRAF or MEK inhibitors in BRAF mutant cancers.
Corcoran RB, Settleman J, Engelman JA. Corcoran RB, et al. Among authors: settleman j. Oncotarget. 2011 Apr;2(4):336-46. doi: 10.18632/oncotarget.262. Oncotarget. 2011. PMID: 21505228 Free PMC article. Review.
A three-drug combination to treat BRAF-mutant cancers.
Firestone AJ, Settleman J. Firestone AJ, et al. Among authors: settleman j. Nat Med. 2017 Aug 4;23(8):913-914. doi: 10.1038/nm.4382. Nat Med. 2017. PMID: 28777790 No abstract available.
Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors.
Wilson TR, Fridlyand J, Yan Y, Penuel E, Burton L, Chan E, Peng J, Lin E, Wang Y, Sosman J, Ribas A, Li J, Moffat J, Sutherlin DP, Koeppen H, Merchant M, Neve R, Settleman J. Wilson TR, et al. Among authors: settleman j. Nature. 2012 Jul 26;487(7408):505-9. doi: 10.1038/nature11249. Nature. 2012. PMID: 22763448 Free PMC article.
A therapeutic opportunity in melanoma: ErbB4 makes a mark on skin.
Settleman J. Settleman J. Cancer Cell. 2009 Oct 6;16(4):278-9. doi: 10.1016/j.ccr.2009.09.013. Cancer Cell. 2009. PMID: 19800573
AXL inhibition sensitizes mesenchymal cancer cells to antimitotic drugs.
Wilson C, Ye X, Pham T, Lin E, Chan S, McNamara E, Neve RM, Belmont L, Koeppen H, Yauch RL, Ashkenazi A, Settleman J. Wilson C, et al. Among authors: settleman j. Cancer Res. 2014 Oct 15;74(20):5878-90. doi: 10.1158/0008-5472.CAN-14-1009. Epub 2014 Aug 14. Cancer Res. 2014. PMID: 25125659
Overcoming EMT-associated resistance to anti-cancer drugs via Src/FAK pathway inhibition.
Wilson C, Nicholes K, Bustos D, Lin E, Song Q, Stephan JP, Kirkpatrick DS, Settleman J. Wilson C, et al. Among authors: settleman j. Oncotarget. 2014 Sep 15;5(17):7328-41. doi: 10.18632/oncotarget.2397. Oncotarget. 2014. PMID: 25193862 Free PMC article.
Mechanisms of acquired resistance to targeted cancer therapies.
Lackner MR, Wilson TR, Settleman J. Lackner MR, et al. Among authors: settleman j. Future Oncol. 2012 Aug;8(8):999-1014. doi: 10.2217/fon.12.86. Future Oncol. 2012. PMID: 22894672 Review.
Targeting the RAF-MEK-ERK pathway in cancer therapy.
Montagut C, Settleman J. Montagut C, et al. Among authors: settleman j. Cancer Lett. 2009 Oct 8;283(2):125-34. doi: 10.1016/j.canlet.2009.01.022. Epub 2009 Feb 12. Cancer Lett. 2009. PMID: 19217204 Review.
Cell culture modeling of genotype-directed sensitivity to selective kinase inhibitors: targeting the anaplastic lymphoma kinase (ALK).
Settleman J. Settleman J. Semin Oncol. 2009 Apr;36(2 Suppl 1):S36-41. doi: 10.1053/j.seminoncol.2009.02.006. Semin Oncol. 2009. PMID: 19393834
TAK1 inhibition promotes apoptosis in KRAS-dependent colon cancers.
Singh A, Sweeney MF, Yu M, Burger A, Greninger P, Benes C, Haber DA, Settleman J. Singh A, et al. Among authors: settleman j. Cell. 2012 Feb 17;148(4):639-50. doi: 10.1016/j.cell.2011.12.033. Cell. 2012. PMID: 22341439 Free PMC article.
233 results
Jump to page